Bicycle Therapeutics Announces Pricing of Initial Public Offering

Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, today announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares (ADSs) representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions.